Background: Currently, intensive lipid lowering is recommended in patients with atherosclerotic ischemic stroke or transient ischemic attack. However, the role of statin in cardioembolic stroke is unclear. We investigated the association of statin with pretreatment collateral status in cardioembolic stroke. Methods: A collaborative study from two stroke centers in distinct geographic regions included consecutive patients with acute middle cerebral artery (MCA) infarction due to atrial fibrillation (AF) who underwent cerebral angiography. The relationship between pretreatment collateral grade and the use/dose of statin at stroke onset was assessed. The angiographic collateral grade was evaluated according to the ASITN/SIR Collateral Flow Grading System. Results: Ninety-eight patients (76 statin-naïve, 22 statin users) were included. Compared with statin-naïve patients, statin users were older and more frequently had hypertension, hyperlipidemia and coronary heart disease. Excellent collaterals (grade 3-4) were more frequently observed in statin users (11 patients, 50%) than in statin-naïve patients (21 patients, 27.6%; p = 0.049). The use of atorvastatin 10 mg equivalent or higher doses of statin was associated with excellent collaterals (p for trend = 0.025). In multiple regression analysis, prestroke statin use was independently associated with excellent collaterals (odds ratio, 7.841; 95% confidence interval, CI, 1.96-31.363; p = 0.004). Conclusions: Premorbid use of statin in AF patients is associated with excellent collateral flow. Although most statin trials excluded patients with cardioembolic stroke, our data suggests the possibility that statin may be beneficial in AF-related stroke.

Keywords:
Atrial fibrillation, Collateral flow, Stroke, Statin, Arteriogenesis
1.
Kwee RM, van Oostenbrugge RJ, Prins MH, Ter Berg JW, Franke CL, Korten AG, Meems BJ, van Engelshoven JM, Wildberger JE, Mess WH, Kooi ME: Symptomatic patients with mild and moderate carotid stenosis: plaque features at MRI and association with cardiovascular risk factors and statin use. Stroke 2010;41:1389-1393.
2.
Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, Kasai H, Izawa A, Tomita T, Koyama J: Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study). Circ J 2011;75:633.
3.
Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D: Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-276.
4.
Bang OY, Ovbiagele B, Liebeskind DS, Restrepo L, Yoon SR, Saver JL: Clinical determinants of infarct pattern subtypes in large vessel atherosclerotic stroke. J Neurol 2009;256:591-599.
5.
Muscari A, Puddu GM, Santoro N, Serafini C, Cenni A, Rossi V, Zoli M: The atorvastatin during ischemic stroke study: a pilot randomized controlled trial. Clin Neuropharmacol 2011;34:141-147.
6.
Ni Chroinin D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, Marnane M, Horgan G, Williams EB, Harris D, Kyne L, McCormack PM, Moroney J, Grant T, Williams D, Daly L, Kelly PJ: Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke 2011;42:1021-1029.
7.
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
8.
Bang OY, Saver JL, Buck BH, Alger JR, Starkman S, Ovbiagele B, Kim D, Jahan R, Duckwiler GR, Yoon SR, Vinuela F, Liebeskind DS: Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2008;79:625-629.
9.
Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Ovbiagele B, Lee KH, Liebeskind DS: Collateral flow predicts response to endovascular therapy for acute ischemic stroke. Stroke 2011;42:693-699.
10.
Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Ovbiagele B, Lee KH, Liebeskind DS: Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke. Stroke 2011;42:2235-2239.
11.
Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, Duckwiler GR, Vinuela F, Pineda S, Liebeskind DS: Statin enhancement of collateralization in acute stroke. Neurology 2007;68:2129-2131.
12.
Pourati I, Kimmelstiel C, Rand W, Karas RH: Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003;146:876-881.
13.
Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ: An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005;58:688-697.
14.
Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-587.
15.
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D: Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34:e109-e137.
16.
Tu HT, Campbell BC, Christensen S, Collins M, De Silva DA, Butcher KS, Parsons MW, Desmond PM, Barber PA, Levi CR, Bladin CF, Donnan GA, Davis SM: Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2010;30:389-395.
17.
Soares BP, Chien JD, Wintermark M: MR and CT monitoring of recanalization, reperfusion, and penumbra salvage: everything that recanalizes does not necessarily reperfuse! Stroke 2009;40:S24-S27.
18.
Kimura K, Iguchi Y, Yamashita S, Shibazaki K, Kobayashi K, Inoue T: Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci 2008;267:57-61.
19.
Seet RC, Zhang Y, Wijdicks EF, Rabinstein AA: Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. Arch Neurol 2011;68:1454-1458.
20.
Maas MB, Lev MH, Ay H, Singhal AB, Greer DM, Smith WS, Harris GJ, Halpern E, Kemmling A, Koroshetz WJ: Collateral vessels on CT angiography predict outcome in acute ischemic stroke. Stroke 2009;40:3001-3005.
21.
Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, Klingman JG, Sidney S, Hills NK, Sorel M, Cullen SP, Johnston SC: Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012;43:147-154.
22.
Zbinden S, Brunner N, Wustmann K, Billinger M, Meier B, Seiler C: Effect of statin treatment on coronary collateral flow in patients with coronary artery disease. Heart 2004;90:448-449.
23.
Boodhwani M, Mieno S, Feng J, Sodha NR, Clements RT, Xu SH, Sellke FW: Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine. J Thorac Cardiovasc Surg 2008;135:117-122.
24.
Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-751.
25.
Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
26.
Weis M, Heeschen C, Glassford AJ, Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-745.
27.
Hibbert B, Ma X, Pourdjabbar A, Simard T, Rayner K, Sun J, Chen YX, Filion L, O'Brien ER: Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One 2011;6:e16413.
28.
Jaumdally RJ, Goon PK, Varma C, Blann AD, Lip GY: Effects of atorvastatin on circulating CD34+/CD133+/CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. J Intern Med 2010;267:385-393.
29.
Tongers J, Roncalli JG, Losordo DW: Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvasc Res 2010;79:200-206.
30.
Van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W: Stimulation of arteriogenesis: a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001;49:543-553.
31.
Zacharek A, Chen J, Cui X, Yang Y, Chopp M: Simvastatin increases notch signaling activity and promotes arteriogenesis after stroke. Stroke 2009;40:254-260.
32.
Grundmann S, Piek JJ, Pasterkamp G, Hoefer IE: Arteriogenesis: basic mechanisms and therapeutic stimulation. Eur J Clin Invest 2007;37:755-766.
33.
Ford AL, An H, D'Angelo G, Ponisio R, Bushard P, Vo KD, Powers WJ, Lin W, Lee JM: Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke. Stroke 2011;42:1307-1313.
34.
Jorge PA, Osaki MR, de Almeida E: Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin. Clin Exp Pharmacol Physiol 1997;24:948-953.
35.
Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, Molina CA, Hereu P, Quintana M, Alvarez-Sabin J: Simvastatin in the acute phase of ischemic stroke: A safety and efficacy pilot trial. Eur J Neurol 2008;15:82-90.
36.
Biffi A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, Rost NS: Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke 2011;42:1314-1319.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.